PCV13 recommended for 6- to 18-year-olds at high risk
(HealthDay)—Pneumococcal conjugate vaccine 13 (PCV13) should be administered to certain children aged 6 through 18 years who are at high risk of invasive pneumococcal disease (IPD), according to a policy statement published ...
Nov 26, 2014
0
0